Sepracor sues Barr to protect Xopenex
MARLBOROUGH, Mass. - Sepracor sued Barr Laboratories for various patent infringements on Xopenex on July 12. The suit, filed in the U.S. District Court for the District of Delaware, came after the Woodruff Lake, N.J.-headquartered Barr filed an application for its generic version of Xopenex. Sepracor is asking the court to ban Barr from manufacturing generic Xopenex and deny its application until the last of Sepracor's patents for Xopenex expires in 2021. Xopenex had U.S. sales of $610 million for the year ending in May.